Saturday 17 October 2026
Export TLPH’s income statement to Excel — free account
Talphera, Inc.
TLPH Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 99.6%, EPS grew 40.0% and free cash flow fell 33.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.
1.08
0.01
+0.93%
Follow TLPH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(85.97%) | (114.16%) | (118.40%) | (143.36%) | |
| (47.87%) | (59.60%) | (63.14%) | (69.60%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.21%) | (83.61%) | (82.33%) | (109.25%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(0.27) | (0.27) | (0.16) | (0.16) | |
Free Cash Flow |
(11.18) | (11.36) | (11.29) | (12.27) | |
| Other line items | |||||
Cash ROIC |
(27.63%) | (30.37%) | (28.53%) | (38.97%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,360.33% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,704.23% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
174.65% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 0.80 | 0.79 | 0.81 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.27) | (0.27) | (0.16) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates